# Dose Escalation Study of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies

> **NCT01351350** · PHASE1 · COMPLETED · sponsor: **Millennium Pharmaceuticals, Inc.** · enrollment: 68 (actual)

## Conditions studied

- Advanced Solid Malignancies
- Hematologic Malignancies

## Interventions

- **DRUG:** MLN0128
- **DRUG:** paclitaxel
- **DRUG:** trastuzumab

## Key facts

- **NCT ID:** NCT01351350
- **Lead sponsor:** Millennium Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02-28
- **Primary completion:** 2017-09-15
- **Final completion:** 2017-09-15
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2019-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01351350

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01351350, "Dose Escalation Study of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01351350. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*